Since hesperidin regulated various Bcl-2 family protein expressions (Fig. 9), including Bcl-xL (a BH4-domain-containing Bcl-2 family protein) and Bax, the targeting and/or co-targeting of these proteins by the small molecules and hesperidin is (are) considered to be a promising strategy for hepatic cancer therapy. The gene discussed is BCL2; the disease is liver cancer.